Hot Features
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Ce... MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.043 | 3.28244274809 | 1.31 | 1.56 | 1.27 | 2157018 | 1.41260466 | CS |
| 4 | 0.053 | 4.07692307692 | 1.3 | 1.56 | 1.22 | 917533 | 1.36834976 | CS |
| 12 | -0.187 | -12.1428571429 | 1.54 | 1.58 | 1.16 | 766049 | 1.35927712 | CS |
| 26 | 0.153 | 12.75 | 1.2 | 3.19 | 1.13 | 930929 | 1.66805184 | CS |
| 52 | -0.597 | -30.6153846154 | 1.95 | 3.19 | 0.87 | 731358 | 1.63829823 | CS |
| 156 | -1.047 | -43.625 | 2.4 | 5.99 | 0.82 | 408796 | 1.88824202 | CS |
| 260 | -2.747 | -67 | 4.1 | 9.64 | 0.82 | 361196 | 2.33636024 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.